PRTH-101

PRTH-101 is a first-in-class, humanized monoclonal antibody that specifically targets and blocks Discoidin Domain Receptor 1 (DDR1), a collagen-binding receptor tyrosine kinase highly expressed on tumor cells. DDR1 plays a key role in organizing collagen fibers within the tumor microenvironment, creating a physical barrier that prevents immune cell infiltration and enables tumors to evade immune attack. By binding to DDR1, PRTH-101 disrupts this collagen alignment, loosening the extracellular matrix and allowing T-cells to penetrate the tumor and exert anti-tumor effects. Preclinical studies have shown that PRTH-101 inhibits DDR1 phosphorylation, decreases collagen-mediated cell attachment, blocks DDR1 shedding from the cell surface, reverses immune exclusion by disrupting collagen fiber alignment around tumors, and enhances CD8+ T-cell infiltration into tumors[5][6]. The drug is being developed for use as monotherapy or in combination with pembrolizumab (an anti-PD-1 checkpoint inhibitor) for advanced or metastatic solid tumors[2][3][4][5]. Clinical trials are ongoing to evaluate its safety, tolerability, pharmacokinetics/dynamics, recommended dosing regimens for Phase 2 development, and anti-tumor activity in selected indications[2][4][5].

Other names

anti-DDR1 monoclonal antibody PRTH-101anti-DDR-1 monoclonal antibody PRTH-101anti-DDR 1 monoclonal antibody PRTH-101